{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:47:15Z","timestamp":1783374435375,"version":"3.54.6"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270046"],"award-info":[{"award-number":["81270046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bioorg.2024.108020","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:34:51Z","timestamp":1733333691000},"page":"108020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["An overview of phenylsulfonylfuroxan-based nitric oxide donors for cancer treatment"],"prefix":"10.1016","volume":"154","author":[{"given":"Chao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/antiox8110556","article-title":"Nitric oxide-releasing polymeric materials for antimicrobial applications: a review","volume":"8","author":"Rong","year":"2019","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-022-02590-0","article-title":"Repurposing nitric oxide donating drugs in cancer therapy through immune modulation","volume":"42","author":"Li","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.108020_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113793","article-title":"Historical origins of the discovery of mammalian nitric oxide (nitrogen monoxide) production\/physiology\/pathophysiology","volume":"176","author":"Lancaster","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108020_b0020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nrn2214","article-title":"Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity","volume":"8","author":"Calabrese","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108020_b0025","article-title":"NMDA-induced nitric oxide generation and CREB activation in central nervous system is dependent on eukaryotic elongation factor 2 kinase","volume":"1867","author":"Gladulich","year":"2020","journal-title":"Biochim. Biophys. Acta."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0030","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1038\/s41598-021-86293-0","article-title":"Exposure to low doses of pesticides induces an immune response and the production of nitric oxide in honeybees","volume":"11","author":"Bartling","year":"2021","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108020_b0035","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2174\/0929867328666210707194543","article-title":"Nitric oxide and immune responses in cancer: searching for new therapeutic strategies","volume":"29","author":"Sahebnasagh","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108020_b0040","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd4623","article-title":"Strategies to increase nitric oxide signalling in cardiovascular disease","volume":"14","author":"Lundberg","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"18","key":"10.1016\/j.bioorg.2024.108020_b0050","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b01672","article-title":"Nitric oxide donor-based cancer therapy: advances and prospects","volume":"60","author":"Huang","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112103","article-title":"Nitric oxide suppression by secreted frizzled-related protein 2 drives retinoblastoma","volume":"42","author":"Jayabal","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2024.108020_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2023.106396","article-title":"Anti-cancer effect of Rumex obtusifolius in combination with arginase\/nitric oxide synthase inhibitors via downregulation of oxidative stress, inflammation, and polyamine synthesis","volume":"158","author":"Ginovyan","year":"2023","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/ars.2019.7958","article-title":"Nitric oxide in hematological cancers: partner or rival?","volume":"34","author":"Vivarelli","year":"2021","journal-title":"Antioxid. Redox Signal."},{"issue":"15","key":"10.1016\/j.bioorg.2024.108020_b0070","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/jm100066y","article-title":"Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein","volume":"53","author":"Fruttero","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0075","doi-asserted-by":"crossref","DOI":"10.3892\/ijo_00000079","article-title":"Nitric oxide donors: Novel cancer therapeutics (Review)","author":"Huerta","year":"1992","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108020_b0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjp.0707224","article-title":"Recent developments in nitric oxide donor drugs","volume":"151","author":"Miller","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108020_b0085","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0006-2952(92)90379-W","article-title":"Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans","volume":"44","author":"Feelisch","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108020_b0090","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1039\/D3RA00189J","article-title":"Recent progress in synthesis and application of furoxan","volume":"13","author":"Abu Yousef","year":"2023","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108020_b0095","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.tet.2015.01.031","article-title":"Synthesis of furoxan derivatives: DABCO-mediated cascade sulfonylation\/cyclization reaction of \u03b1-nitro-ketoximes","volume":"71","author":"Zhao","year":"2015","journal-title":"Tetrahedron."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108020_b0100","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.3390\/molecules17067556","article-title":"Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents","volume":"17","author":"Li","year":"2012","journal-title":"Molecules."},{"key":"10.1016\/j.bioorg.2024.108020_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127952","article-title":"Discovery of beta-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents","volume":"40","author":"Hu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.bioorg.2024.108020_b0110","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1021\/jm5007534","article-title":"Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies","volume":"57","author":"Tang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejmech.2018.05.008","article-title":"Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation","volume":"154","author":"Melo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.20442","article-title":"Design and synthesis of novel NO-donor-ferulic acid hybrids as potential antiatherosclerotic drug candidatesa","author":"Li","year":"2011","journal-title":"Drug Dev. Res."},{"issue":"16","key":"10.1016\/j.bioorg.2024.108020_b0125","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1016\/j.bmc.2017.06.023","article-title":"Phenylsulfonylfuroxan NO-donor phenols: Synthesis and multifunctional activities evaluation","volume":"25","author":"Xie","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106174","article-title":"Development of novel nitric oxide-releasing quinolinedione\/furoxan hybrids as NQO1 inhibitors for intervention of drug-resistanthepatocellular cancer","volume":"129","author":"Zhang","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108020_b0135","article-title":"S-Nitrosylation at the intersection of metabolism and autophagy: Implications for cancer","volume":"1878","author":"Guil-Luna","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.108020_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116068","article-title":"A coumarin-furoxan hybrid as novel nitric oxide donor induced cell apoptosis and ferroptosis in NSCLC by promoting S-nitrosylation of STAT3 and negative regulation of JAK2-STAT3 pathway","volume":"222","author":"Cao","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"43","key":"10.1016\/j.bioorg.2024.108020_b0145","doi-asserted-by":"crossref","first-page":"48515","DOI":"10.1021\/acsami.2c15882","article-title":"A supramolecular nitric oxide nanodelivery system for prevention of tumor metastasis by inhibiting platelet activation and aggregation","volume":"14","author":"Yu","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"51","key":"10.1016\/j.bioorg.2024.108020_b0150","doi-asserted-by":"crossref","first-page":"20407","DOI":"10.1021\/jacs.9b10769","article-title":"Diacylfuroxans are masked nitrile oxides that inhibit GPX4 covalently","volume":"141","author":"Eaton","year":"2019","journal-title":"JACS"},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0155","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1021\/jm400393u","article-title":"Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase pi-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability","volume":"56","author":"Fu","year":"2013","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108020_b0160","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1039\/C7NR08176F","article-title":"NO prodrug-conjugated, self-assembled, pH-responsive and galactose receptor targeted nanoparticles for co-delivery of nitric oxide and doxorubicin","volume":"10","author":"Zhang","year":"2018","journal-title":"Nanoscale"},{"issue":"22","key":"10.1016\/j.bioorg.2024.108020_b0165","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1016\/j.bmc.2008.09.063","article-title":"Synthesis, mechanistic studies, and anti-proliferative activity of glutathione\/glutathione S-transferase-activated nitric oxide prodrugs","volume":"16","author":"Chakrapani","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.talanta.2019.06.059","article-title":"4-Bromo-1,8-naphthalimide derivatives as fluorogenic substrates for live cell imaging of glutathione S-transferase (GST) activity","volume":"204","author":"Fujikawa","year":"2019","journal-title":"Talanta"},{"key":"10.1016\/j.bioorg.2024.108020_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128411","article-title":"Synthesis and biological evaluation of N, N-dialkylcarboxy coumarin-NO donor conjugates as potential anticancer agents","volume":"52","author":"Nelson","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108020_b0180","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5887671","article-title":"Oleanolic Acid (OA) targeting UNC5B inhibits proliferation and EMT of ovarian cancer cell and increases chemotherapy sensitivity of niraparib","volume":"2022","author":"Zeng","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.bioorg.2024.108020_b0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.inoche.2018.07.029","article-title":"Synthesis of hollow nanocages MOF-5 as drug delivery vehicle to solve the load-bearing problem of insoluble antitumor drug oleanolic acid (OA)","volume":"96","author":"Zhang","year":"2018","journal-title":"Inorg. Chem. Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22111915","article-title":"Oleanolic acid and its derivatives: biological activities and therapeutic potential in chronic diseases","volume":"22","author":"Ayeleso","year":"2017","journal-title":"Molecules."},{"issue":"15","key":"10.1016\/j.bioorg.2024.108020_b0195","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1021\/jm800167u","article-title":"Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid","volume":"51","author":"Chen","year":"2008","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21020199","article-title":"Synthesis and anticancer activities of glycyrrhetinic acid derivatives","volume":"21","author":"Li","year":"2016","journal-title":"Molecules."},{"issue":"24","key":"10.1016\/j.bioorg.2024.108020_b0205","doi-asserted-by":"crossref","first-page":"12487","DOI":"10.1039\/D2FO02472A","article-title":"Self-assembled glycyrrhetinic acid derivatives for functional applications: a review","volume":"13","author":"Zou","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.bioorg.2024.108020_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1001018","article-title":"Analysis of the network pharmacology and the structure-activity relationship of glycyrrhizic acid and glycyrrhetinic acid","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"22","key":"10.1016\/j.bioorg.2024.108020_b0215","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1016\/j.bmcl.2010.09.070","article-title":"Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents","volume":"20","author":"Lai","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108020_b0220","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fnmol.2017.00310","article-title":"CDDO and ATRA instigate differentiation of IMR32 human neuroblastoma cells","volume":"10","author":"Chaudhari","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bioorg.2024.108020_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105249","article-title":"Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents","volume":"115","author":"Ju","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2024.108020_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24224097","article-title":"Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids","volume":"24","author":"Borella","year":"2019","journal-title":"Molecules."},{"key":"10.1016\/j.bioorg.2024.108020_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106726","article-title":"Discovery of a novel OGT inhibitor through high-throughput screening based on Homogeneous Time-Resolved Fluorescence (HTRF)","volume":"139","author":"Wu","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0240","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/jm5019302","article-title":"Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer","volume":"58","author":"Ai","year":"2015","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108020_b0245","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41401-021-00775-5","article-title":"Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice","volume":"43","author":"Huang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108020_b0250","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"Zundelevich","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108020_b0255","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.cclet.2012.08.007","article-title":"Synthesis and in vitro biological evaluation of farnesylthiosalicylic acid derivatives as anti-tumor carcinoma agents","volume":"23","author":"Ling","year":"2012","journal-title":"Chin. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108020_b0260","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.bmc.2010.03.077","article-title":"Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents","volume":"18","author":"Ling","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108020_b0265","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1021\/jm1014814","article-title":"Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity","volume":"54","author":"Ling","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0270","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.2147\/DDDT.S251144","article-title":"Analysis of the doxorubicin and doxorubicinol in the plasma of breast cancer patients for monitoring the toxicity of doxorubicin","volume":"14","author":"Harahap","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12640-023-00652-5","article-title":"A review on the neurotoxic effects of doxorubicin","volume":"41","author":"Kaminska","year":"2023","journal-title":"Neurotox. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0280","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/0008-5472.516.65.2","article-title":"Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux","volume":"65","author":"Riganti","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108020_b0285","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1021\/ml100302t","article-title":"Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity","volume":"2","author":"Chegaev","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108020_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115323","article-title":"Cisplatin in cancer treatment","volume":"206","author":"Romani","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.108020_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112229","article-title":"Targeting drug delivery system for platinum(\u2163)-Based antitumor complexes","volume":"194","author":"Zhong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108020_b0300","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1039\/b922222g","article-title":"Platinum(II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity","volume":"46","author":"Xue","year":"2010","journal-title":"Chem. Commun. (Camb)."},{"issue":"19","key":"10.1016\/j.bioorg.2024.108020_b0305","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/ic301374z","article-title":"Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: synthesis, DNA interaction, and cytotoxicity","volume":"51","author":"Zhao","year":"2012","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.861288","article-title":"A review on fused pyrimidine systems as EGFR inhibitors and their structure-activity relationship","volume":"10","author":"Yadav","year":"2022","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0315","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-31","article-title":"Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer","volume":"11","author":"Peraldo-Neia","year":"2011","journal-title":"BMC Cancer."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4132\/KoreanJPathol.2013.47.2.107","article-title":"EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast","volume":"47","author":"Hwangbo","year":"2013","journal-title":"Korean J. Pathol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PAI.0b013e3181af7d3f","article-title":"Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors","volume":"18","author":"Lee","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108020_b0330","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MPA.0b013e3182327a03","article-title":"EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer","volume":"41","author":"Oliveira-Cunha","year":"2012","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.canlet.2006.05.018","article-title":"Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma","volume":"248","author":"Liu","year":"2007","journal-title":"Cancer Lett."},{"issue":"7276","key":"10.1016\/j.bioorg.2024.108020_b0340","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.bioorg.2024.108020_b0345","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.05.026","article-title":"Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors","volume":"66","author":"Han","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0350","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1021\/jm400463q","article-title":"Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.bioorg.2024.108020_b0355","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1039\/C4OB00023D","article-title":"Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF-kappaB","volume":"12","author":"Ling","year":"2014","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108020_b0360","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1248\/cpb.c13-00902","article-title":"Synthesis and in vitro biological evaluation of hybrids from tetrahydro-beta-carboline and hydroxylcinnamic acid as antitumor carcinoma agents","volume":"62","author":"Lin","year":"2014","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0365","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cclet.2013.03.006","article-title":"Synthesis and in vitro biological evaluation of nitric oxide-releasing derivatives of hydroxylcinnamic acids as anti-tumor agents","volume":"24","author":"Lu","year":"2013","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108020_b0370","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phymed.2018.09.216","article-title":"A novel hybrid of 3-benzyl coumarin seco-B-ring derivative and phenylsulfonylfuroxan induces apoptosis and autophagy in non-small-cell lung cancer","volume":"52","author":"Dong","year":"2019","journal-title":"Phytomedicine."},{"key":"10.1016\/j.bioorg.2024.108020_b0375","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.phymed.2017.12.029","article-title":"A hybrid of coumarin and phenylsulfonylfuroxan induces caspase-dependent apoptosis and cytoprotective autophagy in lung adenocarcinoma cells","volume":"39","author":"Wang","year":"2018","journal-title":"Phytomedicine."},{"issue":"22","key":"10.1016\/j.bioorg.2024.108020_b0380","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1021\/jm500613m","article-title":"Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0385","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsmedchemlett.8b00125","article-title":"Novel nitric oxide donors of phenylsulfonylfuroxan and 3-benzyl coumarin derivatives as potent antitumor agents","volume":"9","author":"Guo","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.bioorg.2024.108020_b0390","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1021\/acs.jmedchem.2c00608","article-title":"Novel hybrids of 3-substituted coumarin and phenylsulfonylfuroxan as potent antitumor agents with collateral sensitivity against MCF-7\/ADR","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120946","article-title":"Current trends in development of HDAC-based chemotherapeutics","volume":"308","author":"Cheshmazar","year":"2022","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0400","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/metabo11110792","article-title":"Metabolism, HDACs, and HDAC inhibitors: a systems biology perspective","volume":"11","author":"King","year":"2021","journal-title":"Metabolites."},{"key":"10.1016\/j.bioorg.2024.108020_b0405","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113934","article-title":"NO-HDAC dual inhibitors","volume":"227","author":"Omidkhah","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2024.108020_b0415","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1248\/cpb.c14-00449","article-title":"Design, synthesis and biological evaluation of nitro oxide donating N-hydroxycinnamamide derivatives as histone deacetylase inhibitors","volume":"62","author":"Tu","year":"2014","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"10","key":"10.1016\/j.bioorg.2024.108020_b0420","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1021\/acs.jmedchem.5b00317","article-title":"Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor","volume":"58","author":"Duan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104235","article-title":"Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity","volume":"104","author":"Ding","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2024.108020_b0430","doi-asserted-by":"crossref","first-page":"10080","DOI":"10.1021\/acs.jmedchem.3c00977","article-title":"Discovery of the first irreversible HDAC6 isoform selective inhibitor with potent anti-multiple myeloma activity","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108020_b0435","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1039\/C5MD00158G","article-title":"Synthesis and biological evaluation of nitric oxide-releasing hybrids from gemcitabine and phenylsulfonyl furoxans as anti-tumor agents","volume":"6","author":"Li","year":"2015","journal-title":"MedChemComm."},{"key":"10.1016\/j.bioorg.2024.108020_b0440","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2017.03.020","article-title":"Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation","volume":"135","author":"Han","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0445","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmech.2017.05.018","article-title":"Nitric oxide-releasing derivatives of brefeldin A as potent and highly selective anticancer agents","volume":"136","author":"Tian","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108020_b0450","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/acs.jmedchem.6b01075","article-title":"Potent inhibition of nitric oxide-releasing bifendate derivatives against drug-resistant K562\/A02 cells in vitro and in vivo","volume":"60","author":"Gu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.10.013","article-title":"Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities","volume":"160","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0460","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/open.201900228","article-title":"Synthesis and antitumor evaluation of novel hybrids of phenylsulfonylfuroxan and estradiol derivatives","volume":"9","author":"Wan","year":"2020","journal-title":"ChemistryOpen."},{"key":"10.1016\/j.bioorg.2024.108020_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112079","article-title":"Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies","volume":"190","author":"Zang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113701","article-title":"Design, synthesis and biological activity evaluation of novel scopoletin-NO donor derivatives against MCF-7 human breast cancer in vitro and in vivo","volume":"224","author":"Yu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113153","article-title":"Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents","volume":"212","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"43","key":"10.1016\/j.bioorg.2024.108020_b0480","doi-asserted-by":"crossref","first-page":"50682","DOI":"10.1021\/acsami.1c12646","article-title":"Self-assembly dual-responsive NO donor nanoparticles for effective cancer therapy","volume":"13","author":"Gu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces."},{"key":"10.1016\/j.bioorg.2024.108020_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114112","article-title":"Synthesis and biological evaluation of novel hybrids of phenylsulfonyl furoxan and phenstatin derivatives as potent anti-tumor agents","volume":"230","author":"Huang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114832","article-title":"Novel nitric oxide-releasing derivatives of pyranocarbazole as antitumor agents: Design, synthesis, biological evaluation, and nitric oxide release studies","volume":"244","author":"Zang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115192","article-title":"Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer","volume":"250","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2024.108020_b0500","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1021\/acs.jmedchem.3c00954","article-title":"Design, synthesis, and biological evaluation of esculetin-furoxan-DEAC ternary hybrids for anti-triple negative breast cancer","volume":"66","author":"Wen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117530","article-title":"Development of novel quinoline-NO donor hybrids inducing human breast cancer cells apoptosis via inhibition of topoisomerase I","volume":"96","author":"Wu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2024.108020_b0510","doi-asserted-by":"crossref","first-page":"13089","DOI":"10.1021\/acs.jmedchem.4c01070","article-title":"Discovery of NO donor-aurovertin hybrids as dual ferroptosis and apoptosis inducers for treating triple negative breast cancer","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0515","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic cancer chemoresistance to gemcitabine","volume":"9","author":"Amrutkar","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0520","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2017.10.010","article-title":"Gemcitabine and glioblastoma: challenges and current perspectives","volume":"23","author":"Bastiancich","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2024.108020_b0525","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.2147\/IJN.S212978","article-title":"RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bioorg.2024.108020_b0530","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1395299","article-title":"Scutellarin loaded on ultradeformable nanoliposome scutellarin EDTMP (S-UNL-E) promotes osteogenesis in osteoporotic rats","volume":"2022","author":"Teng","year":"2022","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.bioorg.2024.108020_b0535","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/OTT.S187426","article-title":"Scutellarin inhibits the metastasis and cisplatin resistance in glioma cells","volume":"12","author":"Tang","year":"2019","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0540","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bmcl.2012.11.002","article-title":"Design, synthesis and biological evaluation of glucose-containing scutellarein derivatives as neuroprotective agents based on metabolic mechanism of scutellarin in vivo","volume":"23","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0545","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28114284","article-title":"Design and synthesis of brefeldin a-isothiocyanate derivatives with selectivity and their potential for cervical cancer therapy","volume":"28","author":"Wang","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bioorg.2024.108020_b0550","doi-asserted-by":"crossref","DOI":"10.3390\/md16040133","article-title":"Recent synthesis and discovery of brefeldin A analogs","volume":"16","author":"Paek","year":"2018","journal-title":"Mar. Drugs."},{"key":"10.1016\/j.bioorg.2024.108020_b0555","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2018.11.003","article-title":"Synthesis and biological evaluation of bifendate derivatives bearing acrylamide moiety as novel antioxidant agents","volume":"162","author":"Gu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173299","article-title":"6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway","volume":"882","author":"Yu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"49","key":"10.1016\/j.bioorg.2024.108020_b0565","doi-asserted-by":"crossref","first-page":"19634","DOI":"10.1021\/ja208359a","article-title":"Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol","volume":"133","author":"Klaic","year":"2011","journal-title":"JACS."},{"issue":"21","key":"10.1016\/j.bioorg.2024.108020_b0570","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1016\/j.bmc.2016.08.070","article-title":"Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties","volume":"24","author":"Jiang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0575","doi-asserted-by":"crossref","first-page":"e4471","DOI":"10.1210\/clinem\/dgab507","article-title":"Genome-wide association study of estradiol levels and the causal effect of estradiol on bone mineral density","volume":"106","author":"Schmitz","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108020_b0580","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1021\/mp100190f","article-title":"Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges","volume":"7","author":"Verenich","year":"2010","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108020_b0585","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tips.2019.03.002","article-title":"Triptolide and its derivatives as cancer therapies","volume":"40","author":"Noel","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2024.108020_b0590","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.biopha.2017.04.003","article-title":"Toxicity of triptolide and the molecular mechanisms involved","volume":"90","author":"Xi","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108020_b0595","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/cbdd.13120","article-title":"Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives","volume":"91","author":"Shi","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2024.108020_b0600","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejmech.2015.01.040","article-title":"Synthesis, in vitro and in vivo antitumor activity of scopoletin-cinnamic acid hybrids","volume":"93","author":"Li","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108020_b0605","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bmc.2012.10.059","article-title":"Synthesis and biological evaluation of scopoletin derivatives","volume":"21","author":"Cai","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108020_b0610","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1021\/acsomega.2c07742","article-title":"(8-Hydroxyquinoline) gallium(III) complex with high antineoplastic efficacy for treating colon cancer via multiple mechanisms","volume":"8","author":"Zhou","year":"2023","journal-title":"ACS Omega."},{"key":"10.1016\/j.bioorg.2024.108020_b0615","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bioorg.2018.11.047","article-title":"Synthesis of 8-hydroxyquinoline glycoconjugates and preliminary assay of their beta1,4-GalT inhibitory and anti-cancer properties","volume":"84","author":"Krawczyk","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0620","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.biomaterials.2016.10.016","article-title":"Drug self-delivery systems for cancer therapy","volume":"112","author":"Qin","year":"2017","journal-title":"Biomaterials."},{"key":"10.1016\/j.bioorg.2024.108020_b0625","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2017.08.034","article-title":"Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy","volume":"264","author":"Sun","year":"2017","journal-title":"J. Control. Release."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108020_b0630","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26030663","article-title":"Recent advances in the synthesis of beta-carboline alkaloids","volume":"26","author":"Szabo","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.bioorg.2024.108020_b0635","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejmech.2019.02.054","article-title":"beta-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma","volume":"168","author":"Ling","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108020_b0640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097839","article-title":"The role of NQO1 in ovarian cancer","volume":"24","author":"Tossetta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.108020_b0645","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejmech.2017.02.004","article-title":"Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile","volume":"129","author":"Bian","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0650","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejmech.2018.05.025","article-title":"Development of novel amino-quinoline-5,8-dione derivatives as NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities","volume":"154","author":"Ling","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108020_b0655","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bmc.2016.02.047","article-title":"Design, synthesis of phenstatin\/isocombretastatin-oxindole conjugates as antimitotic agents","volume":"24","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2024.108020_b0660","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1021\/jm000045a","article-title":"Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug","volume":"43","author":"Pettit","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127739","article-title":"Synthesis and biological evaluation of pyranocarbazole derivatives as Anti-tumor agents","volume":"33","author":"Liu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108020_b0670","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","article-title":"FAK signaling in human cancer as a target for therapeutics","volume":"146","author":"Lee","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.bioorg.2024.108020_b0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126381","article-title":"The development of FAK inhibitors: a five-year update","volume":"23","author":"Spallarossa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.bioorg.2024.108020_b0680","doi-asserted-by":"crossref","first-page":"12707","DOI":"10.1021\/acs.jmedchem.0c01059","article-title":"Design, synthesis, and biological evaluation of covalent inhibitors of focal adhesion kinase (FAK) against human malignant glioblastoma","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2024.108020_b0685","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012643","article-title":"Pharmacological and therapeutic applications of esculetin","volume":"23","author":"Garg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.108020_b0690","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2015.09.015","article-title":"Esculetin induces apoptosis in human gastric cancer cells through a cyclophilin D-mediated mitochondrial permeability transition pore associated with ROS","volume":"242","author":"Pan","year":"2015","journal-title":"Chem. Biol. Interact."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108020_b0695","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1021\/ol200908r","article-title":"Cell-permeable iminocoumarine-based fluorescent dyes for mitochondria","volume":"13","author":"Guo","year":"2011","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2024.108020_b0700","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2018.02.058","article-title":"Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity","volume":"149","author":"Alonso","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108020_b0705","article-title":"Discovery of aurovertin B as a potent metastasis inhibitor against triple-negative breast cancer: elucidating the complex role of the ATF3-DUSP1 axis","author":"Shen","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"19","key":"10.1016\/j.bioorg.2024.108020_b0710","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1042\/BCJ20200064","article-title":"Exploiting S-nitrosylation for cancer therapy: facts and perspectives","volume":"477","author":"Rizza","year":"2020","journal-title":"Biochem. J."},{"issue":"13","key":"10.1016\/j.bioorg.2024.108020_b0715","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/0008-5472.CAN-18-2839","article-title":"Anti-CD24 antibody-nitric oxide conjugate selectively and potently suppresses hepatic carcinoma","volume":"79","author":"Sun","year":"2019","journal-title":"Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T02:02:51Z","timestamp":1736474571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824009258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":143,"alternative-id":["S0045206824009258"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108020","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of phenylsulfonylfuroxan-based nitric oxide donors for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108020"}}